Genmab — Januar 2016
-
Imens Udvikler J&J videre på det bedste stof der har potentialet til at lave et paradigmeskift og revolutionere markedet, samtidig med at google i 2025 har deres robotgravere klar. Spændende tid og vi må håbe at det lykkedes at gennembryde pansret for en af dem. Det er sjovt at tænke sig hvor langt forskningen ville være kommet i offentlig regi som socialisterne med Hillary i spidsen higer efter. De slås jo nærmest om at nå målet først de forskellige storspillere, dejligt med konkurrence.
-
Mere nyt om Hexa:A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent Formation of IgG Hexamers at the Cell Surface. http://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.1002344
-
Svært stof, men afsluttende citat: Interestingly, the E345K and E430G mutations, introduced into CD20 mAb 7D8, provided strongly enhanced CDC of patient cells (Fig 7). Moreover, both mutations enabled killing of 5 out of 6 patient CLL cells by RTX, where wild-type RTX was unable to induce CDC.
-
IgG1 backbones with preferred mutations E345K or E430G conveyed a strong ability to induce conditional complement-dependent cytotoxicity (CDC) of cell lines and chronic lymphocytic leukemia (CLL) patient tumor cells, while retaining regular pharmacokinetics and biopharmaceutical developability
-
Developing Antibody-Drug Conjugates for the Treatment of Solid Cancers
Antibodies i Kina: Parren PaulPaul W.H.I. Parren, Ph.D., Senior Vice President & Scientific Director, Genmab. http://www.pegsummitchina.com/cancer-biotherapeutics/ -
Chemical engineering of antibodies, fueled by recent molecular insights, is providing important opportunities for the development of more potent antibody therapeutics. The progress in two antibody-drug conjugate programs from Genmab’s portfolio will be highlighted.
-
Genmab har i det hele taget gang i ADC: Our method enables functional screening of large antibody libraries to identify therapeutic antibody candidates with internalization characteristics favorable for the development of ADCs. http://jbx.sagepub.com/content/21/1/12.abstract?rss=1
-
-
http://www.fool.com/investing/general/2016/01/12/johnson-johnsons-ceo-just-tipped-his-cap-in-a-big.aspx?source=eogyholnk0000001&utm_content=buffer68abe&utm_medium=social&utm_source=twitter.com&utm_campaign=buffer Darzalex den første i en række af blockbusters til JNJ
-
Tak for link solsen. Exciting Stuff. Og US ser ud til at stabilisere sig.
-
Tak Solsen.
-
det her link er hellere ikke så dårligt http://www.mmm-online.com/pipeline/new-multiple-myeloma-drugs-prompt-cost-effectiveness-report/article/464497/
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind